Metabolic associated fatty liver disease (MAFLD) is one of the most common chronic diseases characterized by increased fat accumulation in the liver and metabolic dysfunction. MAFLD is now taking on the character of a pandemic. In addition to dietary therapy and physical activity, hepatoprotectors are included in the pharmacotherapy of MAFLD. This study was to perform a comparative analysis of the efficacy of some hepatoprotectors in experimentally induced MAFLD in adult Wistar rats.